英文药名：Bosulif（Bosutinib Hydrate Tablets）
Bostinib体外抑制BCR-ABL融合基因阳性人慢性粒细胞白血病来源的细胞系（KU 812，K 562，Meg-01，Lama 84和KCL 22）的增殖。 此外，通过施用bostinib皮下移植K562细胞系的裸鼠中观察到肿瘤生长抑制作用和存活的延长。
Acquired manufacturing and marketing authorization for "Bosliff ® tablet 100mg" for treatment of chronic myelogenous leukemia
~ For chronic myelogenous leukemia, new treatment options
Pfizer Inc.(Headquarters: Shibuya-ku, Tokyo; President: Ichiro Umeda, hereinafter referred to as "Pfizer") announced on September 26(Fri) 2014, "Chronic myelogenous leukemia resistant or intolerable to pre-Manufacture of oral SRC/ABL tyrosine kinase inhibitor "Boschlaf®tablet 100mg"(generic name: Bosutibibu, hereinafter "Boshurif") with the efficacy and effect of the oral SRC /ABL tyrosine kinase inhibitor(hereinafter, "chronic myeloid leukemia"We obtained sales approval.
Treatment with selective BCR-ABL tyrosine kinase imatinib, dasatinib or nilotinib, or allogeneic hematopoietic cell transplantation is currently being performed as the primary treatment option for CML.
However, medical needs in the second and third and subsequent treatments are still high, as patients with sufficient first-line treatment can not obtain a therapeutic effect, or there are patients who need to be discontinued due to side effects.
Boschliff is a candidate for CML patients with imatinib resistant or intolerable (second line) treatment in overseas and domestic clinical trials and also for CML patients with dasatinib or nilotinib resistant or intolerable (after tertiary therapy) Efficacy was recognized for patients, and tolerability was good.
This approval is based on these test results.
In addition, this drug was designated as a drug for rare diseases (Orphan drug) with the same efficacy and was under review as a priority review item.
Overview of Bosliff
Bosliff®tablet 100mg(BOSLIF®Tablets 100mg)
Selling approval acquisition date September 26, 2014
Pfizer Japan Inc
Chronic myelogenous leukemia resistant or intolerant to pretreatment drugs
Usually, adults receive 500 mg once a day as a bostinib orally after meals. Although it may be increased or decreased according to the condition of the patient, it can be increased up to 600mg once a day.